Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2

Glycobiology

Volumn 19, Issue 3, 2009, Pages 229-239

  Chung, Tae Wook ^a   Kim, Seok Jo ^a   Choi, Hee Jung ^a   Kim, Keuk Jun ^b   Kim, Mi Jin ^b   Kim, Sung Hoon ^c   Lee, Hyo Jeong ^c   Ko, Jeong Heon ^d   Lee, Young Choon ^e   Suzuki, Akemi ^f   Kim, Cheorl Ho ^a  

^a Sungkyunkwan University   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Kyung Hee University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Dong A University   (South Korea)

^f TOKAI UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Ganglioside GM3; Vascular endothelial growth factor (VEGF); Vascular endothelial growth factor receptor 2 (VEGFR 2)

Indexed keywords

GANGLIOSIDE GM3; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CELL FUNCTION; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; DIMERIZATION; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG PROTEIN BINDING; EMBRYO; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SKIN CAPILLARY; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; G(M3) GANGLIOSIDE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 58949099403     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwn114     Document Type: Article

References (39)

1. Abedi H, Zachary I. 1997. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem. 272:15442-15451.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 331:1480-1487.
3. Alessandri G, Cornaglia-Ferraris P, Gullino PM 1997. Angiogenic and angiostatic microenvironment in tumors-role of gangliosides. Acta Oncol. 36:383-387.
4. Bernatchez PN, Soker S, Sirois MG. 1999. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 274:31047-31054.
5. Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW. 2003. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol. 36:120-127.
6. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF. 1994. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141-1146.
7. Dvorak HF. 2002. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 20:4368-4380.
8. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W. 1998. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci. 111:1853-1865.
9. Feng D, Nagy JA, Dvorak AM, Dvorak HF. 2000. Different pathways of macro-molecule extravasation from hyperpermeable tumor vessels. Microvasc Res. 59:24-37.
10. Ferrara N. 2004. Vascular endothelial growth factors: Basic science and clinical progress. Endocr Rev. 25:581-611.
11. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med. 9:669-676.
12. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182-1186.
13. Fukuda M, Hindsgaul O. 2000. Molecular and Cellular Glycobielogy. New York: Oxford University Press.
14. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for F1k-1/KDR activation. J Biol Chem. 273:30336-30343.
15. Gille H, Kowalski Y, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. 2001. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 276:3222-3230.
16. Giordano FJ, Johnson RS. 2001. Angiogenesis: The role of the microenvironment in flipping the switch. Curr Opin Genet Dev. 11:35-40.
17. Hakomori S. 2002. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA. 99:10231-10233.
18. Ladisch S, Gillard B, Wong C, Ulsh L. 1983. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43:3808-3813.
19. Levitzki A, Mishani E. 2006. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem. 75:93-109.
20. Liu Y, McCarthy J, Ladisch S. 2006. Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res. 66:10408-10414.
21. Manfredi MG, Lim S, Claffey KP, Seyfried TN. 1999. Gangliosides influence angiogenesis in an experimental mouse brain tumor. Cancer Res. 59:5392-5397.
22. Matsumoto T, Claesson-Welsh L. 2001. VEGF receptor signal transduction. Sci STKE. 112:RE21.
23. McMahon G. 2000. VEGF receptor signaling in tumor angiogenesis. Oncologist. 5(Suppl 1):3-10.
24. Miljan EA, Bremer EG. 2002. Regulation of growth factor receptors by gangliosides. Sci STKE. 160:RE15.
25. Miljan EA, Meuillet EJ, Mania-Farnell B, George D, Yamamoto H, Simon HG, Bremer EG. 2002. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem. 277:10108-10113.
26. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9-22.
27. Pal S, Iruela-Arispe ML, Harvey VS, Zeng H, Nagy JA, Dvorak HF, Mukhopadhyay D. 2000. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc Res. 60:112-120.
28. Risau W. 1997. Mechanisms of angiogenesis. Nature. 386:671-674.
29. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D et al. 2005. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell. 7:251-261.
30. Sato Y. 2006. Update on endogenous inhibitors of angiogenesis. Endothelium 13:147-155.
31. Shweiki D, Itin A, Soffer D, Keshet E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843-845.
32. Svennerholm L. 1980. Ganglioside and Synaptic Transmission. New York: Plenum.
33. Takahashi T, Ueno H, Shibuya M. 1999. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 18:2221-2230.
34. Varki A. t993. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology. 3:97-130.
35. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. 1994. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 269:26988-26995.
36. Yoon SJ, Nakayama K, Hikita T, Handa K, Hakomori SI. 2006. Epidermal growth factor receptor tyrosine kinase is modulated by GM3 interaction with N-linked GlcNAc termini of the receptor. Proc Natl Acad Sci USA. 103:189817-18991.
37. Zeng G, Gao L, Birkle S, Yu RK. 2000. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res. 60:6670-6676.
38. Ziche M, Alessandri G, Gullino PM 1989. Gangliosides promote the angiogenic response. Lab Invest. 61:629-634.
39. Ziche M, Morbidelli L, Alessandri G, Gullino PM. 1992. Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio. Lab Invest. 67:711-715.